UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Oil Prices Surge Over $5 as Trump Vows to Continue Iran Strikes 
Iran's Stranglehold on the Strait of Hormuz: What It Means for Global Markets 
Vietnam GDP Growth Slows in Q1 2026 Amid Middle East Oil Crisis 
China's Energy Resilience Shields Economy From Global Oil Shock, Goldman Sachs Says 
Morgan Stanley: Fed Rate Cuts Still on Track Despite Oil-Driven Inflation 
Asian Stocks Drop as Trump Signals Iran War Escalation 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Escalation 
Trump Expands Tariffs on Pharmaceuticals and Metals One Year After Liberation Day 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
U.S. Job Market Braces for Slow Recovery Amid Middle East Tensions and Economic Uncertainty 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Trump's FY2027 Budget: Major Defense Boost and Domestic Spending Cuts 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
CHA Healthcare Co., a South Korean medical hospital operator, announced on Monday, June 28, that it has secured management rights to Fertility Specialists of Western Australia (FSWA) via an acquisition deal.
The FSWA is a major fertility center located in Western Australia and it was through City Fertility National Network, an Australian in-vitro fertilization (IVF) service group, that CHA Healthcare was able to make the deal. The CFNN is a subsidiary of the Korean healthcare company.
As per The Korea Economic Daily, the FSWA is running two fertility centers in Perth, and centers carry out more than 1,200 IVF treatments per year. This number is said to make up 30% of all the IVF treatments done in the region.
With its acquisition of the Australian fertility center, CHA Healthcare Co. is now aiming to conduct over 10,000 in-vitro fertilization treatments annually by the year 2026. The deal also marks the Korean medical operator's expansion in the Australian infertility treatment market.
The company first entered Australia in 2018 when it purchased the Queensland-based City Fertility, which has seven local fertility facilities. With the addition of FSWA in its acquisition portfolio, CHA Healthcare has now expanded the number of its fertility centers to 18 across AU and is targeting states that have a high percentage of women of childbearing age. Such locations include Sydney, Brisbane, and Melbourne.
"CHA Healthcare has built a solid foundation for international medical care in Australia," Cho Seong Soo, CHA Healthcare's chief executive officer, said in a statement. "We aim to expand the global network in Southeast Asian countries such as Vietnam and Indonesia."
Korea Joongang Daily reported that the deal is in line with CHA Healthcare's move to further boost its presence in the fertility treatment market in Australia. Meanwhile, the Korean healthcare firm was launched in 2013 as a subsidiary of CHA Biotech Co. Ltd, which is the leading stem cell therapeutics developer in the country. Aside from Australia and Korea, the company is also running 81 general acute care medical hospitals and IVF clinics in various countries including Singapore, the U.S., and Japan.
